By Marcus A. Banks
The narrow-spectrum antibiotic CRS3123, being developed by Crestone Inc., better preserved gut microbiome diversity than vancomycin in a phase 2 clinical trial of people with Clostridioides difficile, according to data presented at the ASM Microbe 2025 meeting, in Los Angeles.
This could potentially lower the risk for C. difficile infection (CDI) recurrence. The gut microbiome benefits of CRS3123 were true for both alpha and beta diversity, meaning there was a greater